Related Experiment Videos
Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia
1Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong.
The Journal of Clinical Endocrinology and Metabolism
|September 11, 2001
Summary
Simvastatin, a cholesterol-lowering drug, may improve bone metabolism by increasing serum osteocalcin levels. This prospective study suggests statins could be a future treatment for osteoporosis.
Area of Science:
- Biochemistry
- Pharmacology
- Bone Metabolism
Background:
- Previous studies suggest 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) may benefit bone metabolism.
- Existing epidemiological studies have limitations, including non-prospective designs and varied outcome assessments.
Purpose of the Study:
- To investigate the effect of simvastatin on biochemical bone markers in a prospective study.
- To assess changes in serum osteocalcin and other bone markers after simvastatin treatment.
Main Methods:
- A prospective study involving 17 hypercholesterolemic, non-osteoporotic subjects.
- Treatment with simvastatin 20 mg daily for 4 weeks.
- Measurement of serum osteocalcin, bone-specific alkaline phosphatase, urine deoxypyridinoline, and urine cross-linked N-telopeptides of type I collagen.
Main Results:
- Serum osteocalcin concentration significantly increased (p < 0.05) after 4 weeks of simvastatin therapy.
- No significant changes were observed in serum bone-specific alkaline phosphatase, urine deoxypyridinoline, or urine cross-linked N-telopeptides of type I collagen.
Conclusions:
- Simvastatin demonstrates a beneficial effect on bone metabolism, indicated by increased serum osteocalcin.
- Statins may represent a potential anabolic agent for osteoporosis treatment.
- Further randomized controlled studies are recommended to confirm these findings.